Pharma Startup Strengthens Leadership: Ex-Aberdeen COO Joins Medicus with Stock Options

Rhea-AI Filing Summary

Medicus Pharma (NASDAQ: MDCX) has appointed Andrew Smith as Chief Operating Officer, effective June 30, 2025. Smith, 57, brings over three decades of experience in asset management and financial operations to the emerging growth company.

Key appointment details:

• Base salary: $325,000 annually
• Stock compensation: 100,000 options at $2.60 strike price, vesting quarterly over 5 years
• Prior experience includes CEO roles at SR Asset Management and leadership positions at Aberdeen Asset Management
• Educational background: Executive MBA from INSEAD and HND in Accounting from Glasgow College of Commerce

Smith initially joined as a consultant on May 27, 2025, and currently serves on the board of HazelTree Fund Services while advising Code Registry. The appointment involves no reportable related-party transactions or family relationships with other executives.

Insights

Executive Leadership Analyst

Medicus Pharma appoints experienced financial operations leader Andrew Smith as COO with significant equity-based incentives aligned with long-term growth.

Medicus Pharma's appointment of Andrew Smith as COO represents a strategic executive addition with substantial financial operations expertise. Smith brings over 30 years of leadership experience, primarily in asset management and financial operations at prominent firms including SR Asset Management and Aberdeen Asset Management. His background as both CEO and COO at previous organizations suggests Medicus is strengthening its operational leadership with someone who understands both strategic direction and implementation.

The compensation structure is notable - while the $325,000 base salary is relatively modest for C-suite biotech/pharma positions, the 100,000 stock options at $2.60 with a five-year vesting schedule indicates two important elements: 1) A significant equity-based incentive that aligns Smith's interests with long-term company performance, and 2) A deliberate vesting timeline suggesting the company is planning for extended operational development rather than short-term milestones.

Smith's transition from a consulting role since May 27 to the full COO position by June 30 indicates a thoughtful onboarding process, allowing him to understand the organization before assuming full operational authority. The combination of his financial operations background and the company's emerging growth status suggests Medicus may be preparing for operational scaling, improved financial management, or potential capital raising initiatives where his experience would be particularly valuable.

8-K Event Classification

3 items: 5.02, 8.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 2025-06-23 0001997296 Medicus Pharma Ltd. 0001997296 2025-06-23 2025-06-23 0001997296 exch:XNCM mdcx:CommonSharesNoParValueMember 2025-06-23 2025-06-23 0001997296 exch:XNCM mdcx:WarrantsEachExercisableForOneCommonShareAtAnExercisePriceOfFourPointSixFourPerShareMember 2025-06-23 2025-06-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2025

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario	001-42408	98-1778211
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common shares, no par value		MDCX		NASDAQ Capital Market
Warrants, each exercisable for one common share at an exercise price of $4.64 per share		MDCXW		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO"). Mr. Smith first joined the Company as a consultant on May 27, 2025 and will transition to his new role as COO on or about June 30, 2025.

Mr. Smith joins the Company with over three decades experience and is an accomplished C-suite professional with a successful track record as a leader in asset management and financial operations. Most recently, Mr. Smith served as a Consultant and Business Advisor to Connor Capital SB, LLC ("Connor Capital") from April 2024 to September 2024. Prior to joining Connor Capital, Mr. Smith served as the Chairman and Chief Executive Officer of SR Asset Management, LLC ("SRAM") from January 2017 until its sale in June 2024. Before joining SRAM, Mr. Smith held various leadership positions at Aberdeen Asset Management Inc. ("Aberdeen"), including as the Co-Head of Americas and Chief Operating Officer from 2014 to 2016, as Aberdeen's Chief Financial and Chief Operating Officer and as the Chief Compliance Officer for Aberdeen's North American Closed End Funds from 2005 until 2013, and as the Vice President of Finance & Administration from 2001 until 2004. He currently sits on the board of HazelTree Fund Services and is an advisor to Code Registry. Mr. Smith holds an Executive MBA from INSEAD in Fountainebleau and received an HND in Accounting from Glasgow College of Commerce, Scotland.

The Company entered into an agreement with Mr. Smith to memorialize his employment (the "Employment Agreement"). Pursuant to the terms of the Employment Agreement, Mr. Smith will commence employment as COO on or about June 30, 2025. In this role, Mr. Smith will receive an annual base salary of $325,000. Mr. Smith will also receive a grant of 100,000 stock options covering shares of the Company common stock with a strike price of $2.60 per share, vesting quarterly over the next five years, subject to Mr. Smith's continued service to the Company through each vesting date.

There are no family relationships between Mr. Smith and any director or executive officer of the Company pursuant to Item 401(d) of Regulation S-K and the Company has not entered into any transactions with Mr. Smith that are reportable pursuant to Item 404(a) of Regulation S-K. Except as described above, there are no arrangements or understandings between Mr. Smith and any other persons pursuant to which he will be appointed as an executive officer of the Company.

Item 8.01. Other Events.

On June 23, 2025, the Company issued a press release relating to, among other things, the appointment of Mr. Smith as the Company's COO, as described in Item 5.02 above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated June 23, 2025.
104		Cover Page Interactive Data File (formatted as Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

MEDICUS PHARMA LTD.
By:	/s/ Raza Bokhari
Name:	Dr. Raza Bokhari
Title:	Executive Chairman and Chief Executive Officer

Dated: June 23, 2025

FAQ

Who is MDCX's new Chief Operating Officer appointed in June 2025?

Andrew Smith was appointed as MDCX's new Chief Operating Officer, effective June 30, 2025. He brings over three decades of experience and previously served as Chairman and CEO of SR Asset Management, LLC, and held various leadership positions at Aberdeen Asset Management Inc.

What is the compensation package for MDCX's new COO Andrew Smith?

Andrew Smith's compensation package includes an annual base salary of $325,000 and a grant of 100,000 stock options with a strike price of $2.60 per share, vesting quarterly over five years, subject to continued service with the company.

What is Andrew Smith's professional background before joining MDCX?

Prior to MDCX, Smith served as a Consultant at Connor Capital SB, LLC (April-September 2024), Chairman and CEO of SR Asset Management (2017-2024), and held various roles at Aberdeen Asset Management including Co-Head of Americas and COO (2014-2016). He holds an Executive MBA from INSEAD and an HND in Accounting from Glasgow College of Commerce.

When did MDCX file this 8-K and what was the main purpose?

MDCX filed this 8-K on June 28, 2025, primarily to report the appointment of Andrew Smith as Chief Operating Officer, which was announced on June 23, 2025. The filing details Smith's appointment, compensation package, and professional background.

Is MDCX considered an emerging growth company?

Yes, MDCX is classified as an emerging growth company as indicated by the checked box in the 8-K filing under Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.